Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT04534322

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04534322. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To provide early treatment access and evaluate the safety of melflufen and dexamethasone in patients with triple class refractory (TCR) multiple myeloma (MM).

Study identification

NCT ID: NCT04534322
Recruitment status: Approved For Marketing
Study type: Expanded access
Phase: Not listed
Lead sponsor: Oncopeptides AB; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

Melphalan Flufenamide Drug
Dexamethasone Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Mar 18, 2021

United States locations

U.S. sites: 11
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
Highlands Oncology Group	Springdale	Arkansas	72762	—
Beacon Cancer Care	Coeur d'Alene	Idaho	83814	—
University of Illinois Cancer Center	Chicago	Illinois	60612	—
Weill Cornell Medicine - Multiple Myeloma Center	New York	New York	10065	—
Gabrail Cancer Center	Canton	Ohio	44718	—
Oregon Health & Science University	Portland	Oregon	97239	—
Prisma Health Cancer Institute	Greenville	South Carolina	29605	—
Texas Oncology	Dallas	Texas	75230	—
Community Cancer Trials of Utah	Ogden	Utah	84405	—
Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	—
Northwest Medical Specialties	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04534322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 18, 2021 · Synced Nov 12, 2026